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Abstract
Background: In Papua New Guinea (PNG), combination therapy with amodiaquine (AQ) or chloroquine
(CQ) plus sulphadoxine-pyrimethamine (SP) was introduced as first-line treatment against uncomplicated
malaria in 2000.
Methods: We assessed in vivo treatment failure rates with AQ+SP in two different areas in PNG and
twenty-four molecular drug resistance markers of Plasmodium falciparum were characterized in pre-
treatment samples. The aim of the study was to investigate the association between infecting genotype and
treatment response in order to identify useful predictors of treatment failure with AQ+SP.
Results: In 2004, Day-28 treatment failure rates for AQ+SP were 29% in the Karimui and 19% in the
South Wosera area, respectively. The strongest independent predictors for treatment failure with AQ+SP
were pfmdr1 N86Y (OR = 7.87, p < 0.01) and pfdhps A437G (OR = 3.44, p < 0.01). Mutations found in
CQ/AQ related markers pfcrt K76T, A220S, N326D, and I356L did not help to increase the predictive
value, the most likely reason being that these mutations reached almost fixed levels. Though mutations in
SP related markers pfdhfr S108N and C59R were not associated with treatment failure, they increased the
predictive value of pfdhps A437G. The difference in treatment failure rate in the two sites was reflected
in the corresponding genetic profile of the parasite populations, with significant differences seen in the
allele frequencies of mutant pfmdr1 N86Y, pfmdr1 Y184F, pfcrt A220S, and pfdhps A437G.
Conclusion: The study provides evidence for high levels of resistance to the combination regimen of
AQ+SP in PNG and indicates which of the many molecular markers analysed are useful for the monitoring
of parasite resistance to combinations with AQ+SP.
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Background
The effectiveness of the most widely used first-line anti-
malarials chloroquine (CQ) and sulphadoxine-pyrimeth-
amine (SP) has been heavily compromised by the
emergence and spread of Plasmodium falciparum resistance
to these drugs. In order to improve treatment efficacy and
to delay the development and spread of drug resistance,
there is strong advocacy for combination therapy [1].
Though the combination of 4-aminoquinolines or SP
with artemisinin derivates is recommended, this option is
expensive and several countries have taken an interim step
and chose the inexpensive combination of amodiaquine
(AQ) or CQ plus SP.
Monitoring of parasite resistance is essential in directing
the rational use of antimalarials. Apart from studies
assessing in vivo drug efficacy and in vitro drug sensitivity,
molecular markers have been proposed as a means to
monitor drug resistant malaria [2]. CQ resistance has been
attributed to several mutations occurring in the P. falci-
parum chloroquine resistance transporter gene (pfcrt) and
P. falciparum multidrug resistance gene 1 (pfmdr1). Corre-
lation between molecular markers of CQ resistance and in
vivo treatment outcome has been complex. Whereas sev-
eral studies have shown the key role of pfcrt K76T in con-
ferring  in vivo resistance to CQ [3,4], the relationship
between phenotypic resistance and other pfcrt polymor-
phisms (i.e., C72S/R, M74I/T, N75E/D/K/I, K76T/I/N,
I77T, H97Q/L, A144F/T, L148I, L160Y, I194T, A220S,
Q271E, N326S/D, I356V/T/L and R371T/I), which have
been shown to be associated with CQ resistance in vitro,
has been little studied in the field. Single-base changes in
pfmdr1 N86Y, Y184F, S1034C, N1042D and D1246Y have
been documented in CQ resistant laboratory strains, but a
straightforward association of these polymorphisms with
in vivo CQ resistance has been questioned by several
authors [5,6].
The accumulation of point mutations in P. falciparum
dihydrofolate reductase (pfdhfr) and dihydropteroate syn-
thase (pfdhps), two enzymes in the parasite's folate synthe-
sis pathway, is associated with resistance to SP. Though
the relationship between polymorphisms in these genes
and resistance to SP has been shown in vitro, the correla-
tion of different genotypes and clinical treatment out-
come varies between different epidemiological settings.
Whereas the triple mutation S108N+C59R+N51I in pfdhfr
has been found to be a good molecular marker for SP
resistance by some authors [7-9], others did not confirm
the usefulness of this combination of mutations [10,11].
The quintuple mutation pfdhfr S108N+C59R+N51I plus
pfdhps A437G+K540E has been proposed as a useful indi-
cator for monitoring SP resistance in Africa [12], in the
Amazon region, the quintuple mutation pfdhfr
S108N+N51I+I164L plus pfdhps A437G+K540E has been
shown to be more useful [13]. More recently, several
authors have found the double mutation pfdhfr C59R plus
pfdhps K540E to be sufficient to predict treatment failure
in vivo [14-16]. The most likely reason for these conflicting
reports is the fact that, apart from the infecting genotype,
response to drug treatment is affected by many factors,
such as host immunity, which is related to transmission
intensity, and history of drug use in a given area
[10,17,18]. As a consequence, the patterns as well as the
predictive values of molecular drug resistance markers
may vary between different geographical regions. Another
problem is that most of the studies looked at only few
markers, which does not allow comparing the respective
value of each to monitor parasite resistance to specific
drugs.
After a long history of 4-aminoquinoline use which has
been accompanied by accumulating reports about
increasing levels of AQ and CQ resistance [19,20], official
drug policy for uncomplicated malaria in Papua New
Guinea (PNG) was changed to the combination therapy
of AQ or CQ plus SP in 2000. Although high levels of pol-
ymorphisms in CQ relevant genes pfcrt and pfmdr1, and
also to a lesser extent in key markers responsible for resist-
ance to SP, have already been reported in PNG [21,22],
their association with in vivo treatment outcome has never
been evaluated.
In this study, the genetic profile of parasites collected from
pre-treatment samples of malaria patients attending two
health facilities in PNG with known clinical and parasito-
logical outcomes after treatment with AQ+SP was ana-
lyzed. Twenty-four key markers in pfmdr1, pfcrt, pfdhfr and
pfdhps  were determined using a new DNA microarray-
based technology. The association between parasite
genetic output and treatment response was investigated to
identify the most useful predictors of failure with the cur-
rent first-line regimen in the country.
Materials and methods
In vivo assessment of drug efficacy
Drug efficacy studies were conducted according to the
standardized WHO protocol for low to moderate trans-
mission areas [2] and are described in detail elsewhere
[23]. Children between six months and seven years of age
were enrolled if they were presenting at the health centre
with clinically overt and microscopically confirmed P. fal-
ciparum malaria and no danger signs for severe or compli-
cated malaria or signs of any other disease, malnutrition
or anaemia. Standard AQ plus SP first line-treatment (10
mg AQ per kg on Day 0, 1 and 2, and 25 mg sulphadoxine
per kg plus 1.25 mg pyrimethamine per kg on Day 0) was
administered under supervision over the first three days.
Visits for the follow-up were scheduled on Day 1, 2, 3, 7,
14, and 28. On every visit, patients were clinically exam-Malaria Journal 2008, 7:61 http://www.malariajournal.com/content/7/1/61
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ined and a Giemsa-stained blood slide was taken for the
microscopic assessment of parasitaemia. A blood sample
was taken on Day 0 (pre-treatment sample) and on Days
14 and 28 or any day of treatment failure for molecular
genotyping purposes. At the end of the follow-up, the
patients were classified according to their clinical and par-
asitological responses into early treatment failure (ETF),
late clinical failure (LCF), late parasitological failure
(LPF), or adequate clinical and parasitological response
(ACPR) (WHO, 2003).
Study sites and population
The studies were conducted between October 2003 and
April 2004 in the Karimui area (Simbu Province) and the
South Wosera area (East Sepik Province), two rural places
mesoendemic for malaria but differing with regard to
transmission intensity and drug use patterns [20]. Main
characteristics of the study populations and the two sites
are depicted in table 1.
Scientific approval and ethical clearance for the study was
obtained from the Medical Research and Advisory Com-
mittee (MRAC) of the Ministry of Health in PNG and con-
sent was obtained from parents or legal guardians prior to
recruitment of each patient.
Laboratory analyses
Fingerprick blood samples for molecular genotyping pur-
poses were collected on Day 0 (pre-treatment sample) in
EDTA microtainer tubes. DNA was extracted using
QIAamp® DNA Blood Kit (Qiagen, Hombrechtikon, Swit-
zerland) according to the manufacturer's instructions.
Assessment of single nucleotide polymorphisms (SNPs)
for drug resistant malaria was done for pfmdr1 codons
N86Y, Y184F, S1034C, N1042D and D1246Y, pfcrt
codons K76T, H97Q, T152A, S163R, A220S, Q271E,
N326D/S, I356L/T and R371I, pfdhfr  condons A16V,
N51I, C59R, S108N/T and I164L, and pfdhps  codons
S436A, A437G, K540E, A581G, and A613T/S. The method
is based on parallel PCR amplification of the target
sequences followed by primer extension mediated mini-
sequencing using fluorochrome-labelled ddNTPs. Subse-
quent base calling occurs on a microarray upon sequence
specific hybridization [24].
Assessment of the multiplicity of infection (MOI) in pre-
treatment samples and the differentiation between true
recrudescences and new infections in treatment failure
samples was done by PCR-RFLP analysis of the merozoite
surface protein 2 (msp2) as previously described [25,26].
Statistics
Statistical analyses were performed by the use of STATA
software (version 8.2; Stata Corp., College Station, Texas).
The strength of association was evaluated by calculating
odds ratios (OR). χ2 tests and Fisher's exact test and where
applicable stepwise logistical regression analyses were
used to assess the significance of association between
known risk factors and single or multiple mutations and
treatment failure.
To estimate the allele frequencies of resistance markers in
the study sample set, a non-linear statistical model that
takes into account the effects of varying multiplicity of
infection and assumes that resistant and sensitive parasite
clones are transmitted independently was applied. The
likelihood of a sample containing no resistant clones is (1
- p)n, where p is the frequency for the mutant allele and n
is the multiplicity of infection of the sample. Similarly, the
likelihood for the sample to contain no wild-type allele is
pn and for a mixture of both, a wild-type and a resistant
Table 1: Baseline characteristics of study sites and patients at enrolment
Study site
Characteristics Karimui area (Simbu Province) South Wosera (East Sepik Province)
Study sites n = 80 n = 94
Endemicity* mesoendemic mesoendemic
Transmission intensity§ moderate high
Patients
Weight (mean (95% CI), kg) 13.8 (12.9–14.6) 14.4 (13.8–15.1)
Age (mean (95% CI), yrs) 4.0 (3.7–4.4) 4.5 (4.2–4.8)
Sex: female/n (%) 43/97 (44.3) 59/112 (52.7)
Temperature (mean (95% CI),°C) 38.7 (38.5–38.9) 38.7 (38.4–39.0)
Haemoglobin (mean (95% CI), g/dl) 9.0 (8.6–9.5) 9.0 (8.7–9.3)
Parasite density (geometric mean (range), per µl) 21937 (1120–329400) 40526 (280–774400)
Multiplicity of infection (= MOI) (mean (95% CI)) 1.48 (1.34–1.63) 1.73 (1.59–1.88)
Spleen rate# (% (95% CI)) 43.3 (33.3–53.7) 50.9 (41.3–60.5)
* Assessed by concomitant cross-sectional surveys in both study areas which showed P. falciparum prevalence rates of 11–50% in children aged 2–9 
years (WHO, 2003); § Müller et al., 2003; # proportion of children with enlarged spleenMalaria Journal 2008, 7:61 http://www.malariajournal.com/content/7/1/61
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allele, is 1 - pn – (1 - p)n. The likelihood over the whole
data set for p is computed as the product of this likelihood
over all samples, using values of n derived from msp2 gen-
otyping results. Allele frequencies were added by maxim-
ising this likelihood using a simple one dimensional
search routine. This gave very similar estimates to those
made using a corresponding Bayesian algorithm [27].
Confidence intervals were calculated using bootstrap sam-
pling.
Results
In vivo drug efficacy
A total of 80 patients in Karimui and 94 patients in the
Wosera were enrolled into the study and treated with
AQ+SP (median age of 4 years). Day-28 treatment failure
rates for P. falciparum after PCR-correction, classifying
infections with new and recurrent strains as true recrudes-
cences (i.e., treatment failures), were 29% in the Karimui
and 19% in the Wosera area, respectively (Table 2).
Prevalence and relationship of pfmdr1, pfcrt, pfdhfr and 
pfdhps mutations
Mutation analyses were successfully accomplished in all
174 pre-treatment samples from both study sites. Poly-
morphisms were found in pfmdr1 codons N86Y, Y184F,
and N1042D, pfcrt  codons K76T, A220S, N326D and
I356L, pfdhfr codons C59R and S108N, and pfdhps codons
A437G and K540E. None of the other SNPs (11/24) was
detected as mutated allele in any of the infections ana-
lysed.
Regarding CQ relevant molecular markers, infections with
mutated pfmdr1 N86Y and pfcrt K76T, N326D, I356L and
A220S alleles were with 86%, 91%, 89%, 89%, and 70%
very common, whereas 5%, 1%, 1%, 0%, and 2% of these
infections were mixed with a wild-type allele (Figure 1).
The mutated alleles in pfmdr1 Y184F and pfmdr1 N1042D
were only found in five (3%) and two (1%) samples,
respectively, with the latter being detected as mixed allele
only. Considering relationships of mutated alleles in pfcrt,
the mutations N326D and I356L were always linked, the
double mutation N326D+I356L never occurred without a
mutated allele K76T, and a mutation A220S never
occurred without the triple mutation
K76T+N326D+I356L. Considering pfmdr1, a mutation
N1042D was always linked to a mutated Y184F allele, but
these mutated alleles never occurred together with a N86Y
mutation.
Regarding SP relevant molecular markers, mutations in
pfdhfr S108N and C59R were also very common with 79%
and 77% of infections having a pure mutant, and 91%
and 82% of infections having a mutant or mixed allele,
respectively. Mutated alleles in pfdhps A437G were found
in 13% of all infections whereas in 10% it was detected as
a pure mutant. The pfdhps  K540E mutation was only
found in two samples and was only detected as pure
mutant allele. Pfdhfr C59R was never detected without
pfdhfr S108N, and pfdhps mutations A437G and K540E
were strongly linked to the double mutation pfdhfr
S108N+C59R, with only two of the samples having the
pfdhps A437G mutation with concomitant wild-type alle-
les in pfdhfr.
Association between pfmdr1, pfcrt, pfdhfr and pfdhps 
alleles and treatment outcome
All patient isolates were coded according to presence or
absence of mutant alleles and isolates showing both, wild-
type and mutant allele, were treated as mutant. Likewise,
infecting genotypes were coded according to the most
highly mutated pfmdr1,  pfcrt,  pfdhfr  and  pfdhps  alleles
present in the sample.
Apart from pfmdr1 N86Y (OR = 7.87, 95% CI: 1.03–60.36,
p < 0.01) and pfdhps A437G (OR = 3.44, 95% CI: 1.40–
8.47, p < 0.01), there was no independent marker found
to be significantly associated with treatment failure (Table
3). When known confounding factors, such initial para-
site density, age, and multiplicity of infection (MOI), were
adjusted for in a stepwise logistical regression model, the
significant associations for the two above-mentioned
markers were retained.
Twenty three different genotypes could be discriminated
with regard to mutated gene loci in all four genes analysed
(Table 4). Among those, seven were observed in treatment
failure cases, whereas the remaining 16 were exclusively
found in patients with an adequate treatment response.
Associations between these genotypes and treatment fail-
ure can be summarized as follows. Odds ratios for treat-
ment failure were only increased for genotypes having the
N86Y mutation in pfmdr1  combined with the double
Table 2: Treatment outcomes for amodiaquine plus 
sulphadoxine-pyrimethamine against P. falciparum malaria in 
Papua New Guinea
Study sites
Karimui area South Wosera area
n = 80 n = 94
Outcome*N u m b e r  ( % )
ACPR 57 (71.2) 74 (81.3)
ETF 1 (1.3) 5 (5.5)
LCF 6 (7.5) 1 (1.1)
LPF 16 (20.0) 11 (12.1)
Total TF 23 (28.8) 17 (18.7)
* PCR-corrected values up to Day 28; ACPR, Adequate clinical and 
parasitological response; ETF, Early treatment failure; LCF, Late 
clinical failure; LPF, Late parasitological failure; TF, Treatment failureMalaria Journal 2008, 7:61 http://www.malariajournal.com/content/7/1/61
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Prevalence of mutations in pfmdr1, pfcrt, pfdhfr and pfdhps in patient samples from Papua New Guinea Figure 1
Prevalence of mutations in pfmdr1, pfcrt, pfdhfr and pfdhps in patient samples from Papua New Guinea. CQ, 
chloroquine; SP, sulphadoxine-pyrimethamine; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfcrt, Plasmodium fal-
ciparum chloroquine resistance transporter; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falci-
parum dihydropteroate synthase; no mutation was detected in any of the other SNP sites analysed (13/24 sites).
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Table 3: Association between mutated single markers in pfcrt, pfmdr1, pfdhfr and pfdhps and treatment failure with amodiaquine plus 
sulphadoxine-pyrimethamine
Gene Polymorphism OR 95% Confidence Interval p (LRT)
pfcrt K76T 2.09 0.45–9.70 0.31
pfcrt I326L 2.64 0.58–12.03 0.16
pfcrt N356D 2.64 0.58–12.03 0.16
pfcr A220S 1.23 0.55–2.75 0.62
pfmdr1 N86Y 7.87 1.03–60.36 <0.01
pfmdr1 Y184F §
pfmdr1 N1042D §
pfdhfr S108N 0.74 0.22–2.51 0.64
pfdhfr C59R 2.34 0.77–7.14 0.11
pfdhps A437G 3.44 1.40–8.47 <0.01
pfdhps K540E §
OR, odds ratio; LRT, likelihood ratio test; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfmdr1, Plasmodium falciparum multidrug 
resistance gene 1; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase; § mutated alleles 
were not detected in samples from treatment failure casesMalaria Journal 2008, 7:61 http://www.malariajournal.com/content/7/1/61
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mutation S108N+C59R in pfdhfr, regardless of the con-
comitant genotype in pfcrt. However, the risk for failure
reached only statistical significance for genotypes having
the pfmdr1 N86Y mutation in conjunction with the quad-
ruple mutation K76T+A220S+N326D+I356L in pfcrt and
the A437G allele in pfdhps (OR = 3.84, 95% CI: 1.34–
11.03, p < 0.01). Furthermore, a significant association
was also observed with the genotype harbouring the pfcrt
quadruple mutant plus pfmdr1 N86Y without any concur-
rent mutations in pfdhfr or pfdhps (OR = 7.17, 95% CI:
1.26–40.71, p = 0.02).
Mutant allele frequencies and treatment outcome by site
To investigate whether the difference in treatment out-
come at the two study sites was reflected in the drug resist-
ance profile of the corresponding parasites, mutant allele
frequencies for each gene locus were calculated. Maxi-
mum likelihood estimates of mutant allele frequencies
found in the two study populations are presented in Fig-
ure 2. Regarding the allele frequencies for the CQ relevant
molecular markers, there was no significant difference in
pfcrt K76T, N326D, and I356L. The only statistically sig-
nificant differences in allele frequencies between the Kar-
imui and the Wosera area were found for pfcrt  A220S
(0.56 versus 0.81, p < 0.0001), pfmdr1 N86Y (0.99 versus
0.70, p < 0.0001) and pfmdr1 Y184F (0.00 versus 0.04, p =
0.001). A similar picture was observed for the SP relevant
molecular markers. Whereas the difference in any of the
mutated loci in pfdhfr was not significant, the genetic pro-
file for pfdhps mutation A437G was significantly different
in the two parasite populations with an allele frequency of
0.25 in the Karimui area versus 0.02 in the Wosera area (p
< 0.0001).
Discussion
The genetic drug resistance profile was established in pre-
treatment samples from malaria patients in Karimui and
the Wosera by the use of a new DNA microarray-based
technology [24] and its relationship with in vivo drug
response to the combinations of AQ+SP was analysed.
The principal objectives were to establish the baseline
prevalence of polymorphisms in genes related to AQ/CQ
and SP resistance, to assess their relationship with treat-
ment outcome, in order to identify and propose useful
Table 4: Association between infecting pfcrt, pfmdr1, pfdhfr and pfdhps genotypes and treatment failure with amodiaquine plus 
sulphadoxine-pyrimethamine
CQ-relevant markers SP-relevant markers
pfcrt pfmdr1* pfdhfr pfdhps
K76T N326D I356L A220S N86Y S108N C59R A437G K540E P (%) OR 95% CI p (χ2)
1.2 §
X 0.6 §
XX 1.7 §
X 0.6 §
XX X 0.6 §
XXX XX 0.6 §
XXX X 0.6 §
XXX X X 0.6 §
XXX X XX 7 . 0 0.28 0.03–2.24 0.16
X 0.6 §
XX 1.2 §
XX X 3 . 5 1.67 0.29–9.48 0.57
XX X X 0.6 §
XXX X 0.6 §
XXX X X 1.2 §
X X X X X X 11.7 1.10 0.38–3.25 0.86
XXX X XXX 3 . 5 3.46 0.67–17.86 0.15
XXX X X 3 . 5 7.17 1.26–40.71 0.02
XXX X X X 1.2 §
XXX X X X 6.4 §
X X X X X X X 42.7 1.00 0.48–2.03 0.98
XXX X X XXX 9 . 3 3.84 1.34–11.03 <0.01
XXX X X XX X 0.6 §
* due to very low mutation rates, genotypes with mutated gene loci Y184F and N1042D in pfmdr1 were grouped together with the wild-type 
pfmdr1 genotypes; AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfmdr1, 
Plasmodium falciparum multidrug resistance gene 1; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum 
dihydropteroate synthase; P, prevalence; OR, odds ratio; X, mutated allele; § the genotype was not detected in samples from treatment failure casesMalaria Journal 2008, 7:61 http://www.malariajournal.com/content/7/1/61
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markers for molecular monitoring of drug resistant P. fal-
ciparum in the country.
The analysis of the genetic profile of the parasite popula-
tion revealed high levels of mutant alleles in CQ resistance
(CQR) related pfcrt and pfmdr1 genes. The long history of
4-aminoquinoline use as monotherapy in PNG has led to
a highly CQ resistant genetic background in the parasites
as reported previously [21,28]. In addition, the results
demonstrated prevalence rates of 91% and 82% for
mutant alleles in the pyrimethamine related gene loci pfd-
hfr S108N and C59R. Mita et al. [29] recently analysed P.
falciparum isolates from patients attending town clinics in
Wewak (East Sepik Province) and observed similarly high
prevalence rates of pfdhfr double S108N+C59R mutations
(83% in 2002 and 86% in 2003). These high levels of
mutation rates in pfdhfr appearing only a short time after
the implementation of SP as one component of the offi-
cial first-line policy were not surprising and may be due to
i) the increasing recourse to SP as second-line therapy
with quinine in the late 1990s (Nsanzabana et al., unpub-
lished), ii) the former drug pressure exerted by the use of
pyrimethamine (in combination with CQ) in mass drug
administration campaigns in the 1960s and 1970s [30],
and iii) the widespread use of trimethoprim-sulphameth-
oxazole for the treatment of bacterial infections [31,32].
Recent microsatellite analysis in dhfr-flanking regions by
Mita et al. [29] revealed that the most prevalent dhfr hap-
lotype (i.e., S108N+C59R double mutation) was associ-
ated with reduced microsatellite variability around the
gene, an observation which argues for the selection of pre-
existing SP resistant parasites, rather than the frequent
emergence of de novo mutations in this gene [33]. These
data further corroborate the hypothesis, that former drug
pressure has lead to the emergence of pyrimethamine
resistant parasites before the official introduction of SP in
PNG.
Until 2003, polymorphic pfdhps  loci associated with
reduced sensitivity to sulpha drugs have only been found
in a single P. falciparum isolate originating from PNG
[21,22]. In the present study, prevalence rates of 13% for
A437G and 1% for K540E were observed. Likewise, Mita
and colleagues detected mutations in these loci in 8% of
patient isolates collected in Wewak in the year 2003. In
the view that pfdhfr mutations usually predominate over
Maximum likelihood estimates of mutant allele frequencies at the two study sites Figure 2
Maximum likelihood estimates of mutant allele frequencies at the two study sites. Error bars denote 95% confi-
dence intervals; * denotes statistical significance at the 95% level; CQ, chloroquine; SP, sulphadoxine-pyrimethamine; pfmdr1, 
Plasmodium falciparum multidrug resistance gene 1; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfdhfr, Plas-
modium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase.
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those in pfdhp [12,15], the detection of genotypes having
a single dhps A437G mutation in combination with pfdhfr
wild type alleles in two of the samples was rather unusual.
However, this genotype may well have been selected by
sulpha drugs used to treat infectious diseases other than
malaria.
In order to propose a suitable marker set for the molecular
monitoring of P. falciparum against the current combina-
tion therapy, the association of single mutations as well as
infecting genotypes with in vivo treatment response was
investigated. Regarding CQ relevant markers, the only sin-
gle marker associated with a significantly increased risk of
treatment failure was pfmdr1 N86Y. Taking into account
additional SNPs in pfcrt, neither of the mutated alleles
increased the predictive value for pfmdr1 N86Y, the most
likely reason being that these mutations nearly reached
fixed levels in the parasite population. Similarly,
pyrimethamine relevant markers in pfdhfr did not show a
significant association with treatment failure. Risk of fail-
ure was only increased with infections harbouring the
A437G mutation in pfdhps. These observations are in
agreement with previous studies showing that the preva-
lence of single molecular markers (e.g. pfcrt K76T or pfdhfr
S108N) was almost always higher than the level of clinical
or parasitological resistance to the respective drugs, espe-
cially in regions with high transmission intensity and long
lasting drug pressure [4,34] and therefore, renders these
markers unsuitable for molecular monitoring. Further-
more, the validity of molecular markers is dependent on
former drug use and may also vary according to the
malaria epidemiology in a given area [10,17,18]. The eval-
uation and assessment of a combination of markers,
instead of single markers indicating the presence of a
highly resistant genotype, have been suggested for the
molecular monitoring of antimalarial resistance [12,14-
16,35,36]. In the present study, which took into account
the combined pfcrt/pfmdr1/pfdhfr/pfdhps genotype, the risk
of treatment failure was clearly associated with the total
number of mutations in the analysed genes. The risk was
significantly increased for patients harbouring parasites
with the most highly mutated genotype (i.e., 8/24 SNPs
mutated). However, unusual findings included the
increased risk of treatment failure with genotypes having
the N86Y mutation in pfmdr1 and the quadruple muta-
tion in pfcrt combined with a fully wild type pfdhfr+pfdhps
allele. These results highlight again the fact that among
many parasite and host factors, the molecular resistance
background of P. falciparum is only one of several determi-
nants for in vivo treatment outcome. Whereas acquired
immunity can account for the clearance of drug resistant
genotypes, diminished drug metabolism may well explain
treatment failure in spite of an infection with a susceptible
genotype [37].
Regarding former drug history in PNG, the relevance of
key pfdhps mutations in predicting treatment failure was
expected. AQ and CQ as inefficacious partner drugs of SP
in the new standard regimen were not able to curb both,
the progression of pyrimethamine resistance as well as the
emergence of sulphadoxine resistance. It is most likely
that in this sample, clinical efficacy of the sulpha compo-
nent was mainly assessed. However, according to the
present results, also pfmdr1 N86Y plays an important role
in predicting a negative treatment response. CQ and AQ
are chemically related drugs and cross-resistance has been
described in several clinical and in vitro reports. Though
little is known about the genetic mechanisms conferring
AQ resistance [38], an important role has been ascribed to
the key CQR markers pfcrt K76T and pfmdr1 N86Y [39,40].
It has been shown recently that in combination with pfcrt
K76T, the pfmdr1 N86Y polymorphism was predictive for
treatment failure with AQ in Nigeria [41] and that AQ
resistance was associated with the selection of these poly-
morphisms in Kenya [42]. Considering the long use of AQ
as monotherapy against uncomplicated falciparum
malaria in PNG and the observation that pfmdr1 N86Y is
a strong predictor for treatment failure with AQ+SP, the
present data support the hypothesis that pfmdr1 N86Y is
probably involved in AQ resistance. Several studies have
shown that both, SNPs and gene amplification of pfmdr1,
can mediate resistance to 4-aminoquinlines and also
other drug classes, such as amino alcohols and artemisi-
nin derivates [43] However, results from different studies
investigating the relationship of these genetic alterations
in pfmdr1 and in vivo response were often inconsistent
[6,44]. Direct (active drug translocation) and indirect
(modification of biophysical cell parameters) modes of
action have been proposed for P-glycoprotein homolog 1,
the gene product of pfmdr1. But how genetic alterations in
pfmdr1 and epistatic interactions with other genes finally
lead to a multidrug resistant phenotype remains to be
resolved [45].
Finally, the fact that the difference in clinical outcome
between the two sites was reflected in the genetic profile
of the corresponding parasite populations, especially for
the frequencies of pfmdr1 N86Y and pfdhps A437G, further
confirmed the role of these two markers as important pre-
dictors for a negative treatment response with AQ+SP and
suggests them to be the most useful resistance surveillance
markers with the current standard treatment in PNG.
Conclusion
This study shows that a careful baseline assessment of
molecular markers, including the investigation of their
relationship with treatment response, is essential for the
identification of appropriate marker sets. For the parallel
analysis of SNPs in multiple genes in a large sample size,
DNA microarray technology has proven to be a valuableMalaria Journal 2008, 7:61 http://www.malariajournal.com/content/7/1/61
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and cost-effective tool. However, the use of additional
markers could become necessary for the longitudinal
resistance monitoring in the future, in particular when
current drug policy starts to show reduced effectiveness.
These may include SNPs in known or as yet uncharacter-
ized genes involved in resistance to the commonly used
antimalarials, or markers against newly implemented
drug classes, such as the artemisinins.
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